Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/20/2025

Safety of Colchicine with Direct Oral Anticoagulants (DOACs)

Pharmacological Considerations

  • DOACs (apixaban, rivaroxaban, edoxaban, and dabigatran) are substrates of P-glycoprotein (P-gp) transporters, with rivaroxaban and apixaban also being metabolized by CYP3A4 enzymes 1
  • Unlike many cancer therapeutics and other medications that are potent inhibitors of P-gp or CYP3A4, colchicine does not appear in guidelines as requiring special consideration when used with DOACs 1, 3

Clinical Implications

  • The International Society on Thrombosis and Haemostasis (ISTH) guidelines recommend individualized treatment regimens after shared decision-making with patients regarding anticoagulation, but do not specifically mention colchicine as a medication of concern 3, 4

Bleeding Risk Considerations

  • Patients with additional risk factors for bleeding, such as renal or hepatic impairment, thrombocytopenia, or prior history of GI bleeding, should be appropriately monitored when on any anticoagulant therapy, including when combined with colchicine 6
  • The ISTH guidelines note that particular caution for DOAC use is warranted in settings associated with an increased risk for bleeding, but this is a general precaution not specific to colchicine use 4

Monitoring Recommendations

  • Regular assessment of renal function is recommended for patients on DOACs, as all DOACs have some degree of renal elimination (dabigatran ~80%, edoxaban ~50%, rivaroxaban ~33%, apixaban ~25%) 7
  • Individual patient factors such as age, renal function, and concomitant medications should still be considered when prescribing any medication to patients on anticoagulation 7